Copyright
©The Author(s) 2022.
World J Hepatol. Apr 27, 2022; 14(4): 719-728
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.719
Published online Apr 27, 2022. doi: 10.4254/wjh.v14.i4.719
Characteristic | Total | Mild PPF (C pattern) | Significant PPF (D/E/F pattern) | P value |
n | 41 | 10 | 31 | - |
Age (yr) | 57 (18-80) | 48.1 (18-75) | 57.2 (25-80) | 0.0865a |
Sex | 0.4820b | |||
Male | 17 (41%) | 5 (40%) | 12 (39%) | |
Female | 24 (59%) | 5 (50%) | 19 (61%) | |
AST (U/L) | 29.0 ± 2.6 | 24.3 ± 1.9 | 30.0 ± 2.9 | 0.3328c |
ALT (U/L) | 29.0 ± 2.2 | 26.2 ± 4.5 | 30.0 ± 3.2 | 0.4584c |
ALP (U/L) | 262 ± 33 | 329 ± 113 | 238 ± 22 | 0.6379c |
GGT (/LSN) | 62 ± 12 | 35 ± 16 | 71.2 ± 14.0 | 0.0013c |
Platelets count (/mm3) | 131 ± 12 | 218 ± 15 | 102 ± 11 | 0.0001c |
Total Cholesterol (mg/dL) | 169.0 ± 4.6 | 174.0 ± 7.2 | 167.8 ± 5.6 | 0.4626c |
HDL (mg/dL) | 45.7 ± 2.0 | 49 ± 5.7 | 44.6 ± 2.0 | 0.4863c |
LDL (mg/dL) | 105.0 ± 3.8 | 108 ± 4.7 | 104 ± 4.8 | 0.3760c |
Glucose (mg/dL) | 93.6 ± 5.2 | 97 ± 14 | 92 ± 5.1 | 0.9451c |
Metabolite | Chemical shift (δ/ppm) | Metabonomics formalism | Higher serum level |
Valine | 1.030 | OPLS-DA | Mild PPF |
No identified | 1.046 | OPLS-DA | Mild PPF |
Alanine | 1.446 and 1.502 | PLS-DA and OPLS-DA | Significant PPF |
N-acetylglucosamine | 1.975 up to 2.011 | PLS-DA | Significant PPF |
Glycolaldehyde | 3.492 | PLS-DA | Significant PPF |
Carbohydrates | 3.544; 3.692; and 3.808 | PLS-DA and OPLS-DA | Mild PPF |
Classification from WHO Niamey Protocol | ||||
Significant PPF | Mild PPF | P valuea | ||
Metabonomics Model | Significant PPF | 28 | 0 | < 0.0001 |
Mild PPF | 3 | 10 |
- Citation: Rodrigues ML, da Luz TPSR, Pereira CLD, Batista AD, Domingues ALC, Silva RO, Lopes EP. Assessment of periportal fibrosis in Schistosomiasis mansoni patients by proton nuclear magnetic resonance-based metabonomics models. World J Hepatol 2022; 14(4): 719-728
- URL: https://www.wjgnet.com/1948-5182/full/v14/i4/719.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i4.719